Skip to main content
Signal8

Surgery Partners, Inc. (SGRY) Form 8-K — Nov 9, 2026

$SGRYForm 8-KItems 2.02, 9.01Filed Nov 9, 2026, 4:12 PM ET0001638833-26-000089Original filing

Surgery Partners reported Q3 2026 revenue of $815.3 million, down 0.8% YoY, with a net loss attributable to the company of $21.1 million and Adjusted EBITDA of $132.7 million versus $136.4 million a year ago. Same-facility revenues grew 6.0%, masking consolidated softness tied to the Idaho Falls divestiture. The company also amended its merger agreement with HealthSpan Partners, raising the cash consideration to $25.00 per share (enterprise value up to ~$6.0 billion) after receiving an unsolicited competing proposal. A new Ticking Fee pays non-Bain stockholders 10% per annum monthly if the deal slips past March 1, 2027.

Key figures

Revenue
815300000
Revenue Yoy
-0.8%
Cash Position
354500000
Enterprise value
~$6.0 billion
Ticking fee rate
10% per annum on $25.00 per share if merger not closed by March 1, 2027
Revolver capacity
$692.8M
Adjusted ebitda q3
$132.7M vs $136.4M prior year
Net debt to ebitda
4.4x
Adjusted ebitda ytd
$360.2M vs $369.3M prior year
Merger price per share
$25.00
Operating cash flow q3
$103.5M vs $83.6M prior year
Same facility revenue growth q3
6.0%

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.